Table 1.
Double-blind, randomized, placebo-controlled trials using anti-inflammatory drugs in mild-to-moderate AD patients.
| Drug | Dose (mg/day) | Therapy duration (month) | Number of patients | Main effect | References |
|---|---|---|---|---|---|
| Celecoxib | 400 | 12 | 285 | Neutral | (207) |
| Celecoxib | 400 | 12 | 425 | Neutral/detrimental | (208) |
| Dapsone | 100 | 12 | 201 | Neutral | (209) |
| Diclofenac | 50 | 6 | 41 | Beneficial | (210) |
| Hydroxychloroquine | 200–400 | 18 | 168 | Neutral | (211) |
| Ibuprofen | 800 | 12 | 132 | Neutral | (212) |
| Indomethacin | 100–150 | 6 | 44 | Beneficial | (213) |
| Indomethacin | 100 | 12 | 51 | Beneficial | (214) |
| Naproxen | 440 | 12 | 351 | Neutral | (215) |
| Nimesulide | 200 | 3 | 40 | Neutral | (216) |
| Prednisone | 10 | 12 | 138 | Neutral/detrimental | (217) |
| Rofecoxib | 25 | 12 | 351 | Neutral/detrimental | (215) |
| Rofecoxib | 25 | 12 | 692 | Neutral | (218) |
| Tarenflurbil | 800–1,600 | 12 | 210 | Neutral | (219) |
| Tarenflurbil | 1,600 | 18 | 1,684* | Neutral/detrimental | (220) |
| Tarenflurbil | 1,600 | 18 | 840* | Neutral | (221) |
*
Patients with mild AD.
AD, Alzheimer's disease.